Yi-Jong Lin

Consejero General en TaiGen Biotechnology Co., Ltd. .

Health Technology

Consumer Non-Durables

Consumer Services

Perfil

Yi-Jong Lin is a professional who currently holds the position of Vice President-Regulatory Affairs at TaiGen Biotechnology Co., Ltd.
Prior to this, he worked as a Principal at Colgate-Palmolive Co. and Eisai Medical Research, Inc. Dr. Lin received his graduate and doctorate degrees from the University of Tokyo.

Cargos activos de Yi-Jong Lin

Empresas	Cargo	Inicio
TaiGen Biotechnology Co., Ltd. TaiGen Biotechnology Co., Ltd. Pharmaceuticals: MajorHealth Technology TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company engaging in the development of therapeutics for infectious diseases, cancer, and diabetes-related complications. Its activities include drug discovery, development, global regulatory, and commercialization in China. The company was founded by Ming-Chu Hsu in 2001 and is headquartered in Taipei, Taiwan.	Consejero General	11/01/2010

Todos los cargos activos de Yi-Jong Lin

Antiguos cargos conocidos de Yi-Jong Lin.

Empresas	Cargo	Fin
COLGATE-PALMOLIVE COMPANY	Corporate Officer/Principal	-
Eisai Medical Research, Inc.	Corporate Officer/Principal	-

Ver el detalle de la experiencia de Yi-Jong Lin.

Formación de Yi-Jong Lin.

University of Tokyo

Doctorate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Yi-Jong Lin.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	1
COLGATE-PALMOLIVE COMPANY	Consumer Non-Durables

Empresas privadas	2
TaiGen Biotechnology Co., Ltd. TaiGen Biotechnology Co., Ltd. Pharmaceuticals: MajorHealth Technology TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company engaging in the development of therapeutics for infectious diseases, cancer, and diabetes-related complications. Its activities include drug discovery, development, global regulatory, and commercialization in China. The company was founded by Ming-Chu Hsu in 2001 and is headquartered in Taipei, Taiwan.	Health Technology
Eisai Medical Research, Inc.